CBD Health Foods Ltd, trading as British Cannabis, is pleased to announce that it has entered into an exclusive Trademark & Know-How License Agreement with Elixinol Wellness Limited to sell CBD products across the UK.
Given the complex and ongoing developments with the regulatory environment in the UK and given Elixinol’s strategic focus on driving profitability, Elixinol made the considered decision in 2021 to cease trading in the UK and EU markets and instead move to an indirect route to market model by seeking a licensing partner in the UK.
The Elixinol and British Cannabis agreement enables Elixinol’s strong brand to continue to be distributed in the UK, whilst handing over the UK operations and associated cost.
The appointment of British Cannabis as the sole and exclusive Licensee of Elixinol-branded products in the UK, for a three-year term, marks a pivotal agreement in the course of the UK cannabinoid market.
Both parties are committed to invest in a renewed support of the existing Elixinol sales channels, key retail customers and consumers. The shared aim is to improve revenues across the board, whilst building on the legacy set by Elixinol’s founders over 10 years ago, ensuring a continued execution of Elixinol’s global strategy, .
Established in 2015, British Cannabis is the largest independently owned, producer, manufacturer and distributor of legal cannabis-derived products in the UK. It has a suite of successful branded flagship products, along with a range of white label brands. With a focus on innovation, quality, accuracy and compliance that has backed products from this UK cannabis industry original for over six years, this focus now looks set to support the dynamic range of wellness solutions at Elixinol.
Elixinol Global CEO, Oliver Horn, commented, “We are delighted about our partnership with British Cannabis who are the most established manufacturer and distributor of branded and white label CBD products in the UK. British Cannabis’ Canabidol™ brand is widely distributed in UK pharmacies, demonstrating the company’s credentials and capabilities to build brands in sophisticated retail channels. BRITISH CANNABIS’ manufacturing capability also allows us to manufacture Elixinol products in the UK and thus create a more efficient supply chain solution.
British Cannabis CEO, Tom Whettem, commented “It is an honour to be asked to continue the legacy of Elixinol here in our home market. The prospect of a dynamic partnership between Australia’s leading global CBD range and the UK’s premier manufacturer has excited both myself and our leadership team.
"The ranges from the companies complement each other in several ways and continuing the legacy of Elixinol galvanizes us. With the security of our Novel Foods dossiers, the potential to take this reinforced portfolio to market makes for a very solid proposition for retailers and provides the CBD supplements consumer with great choices," he said.
